Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04462471
Title Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

thyroid gland follicular carcinoma

thyroid gland papillary carcinoma

Therapies

Copanlisib + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities) Recruiting Basking Ridge New Jersey 07920 United States Details
Memoral Sloan Kettering Monmouth (Limited protocol activities) Recruiting Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Recruiting Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) Recruiting Commack New York 11725 United States Details
Memoral Sloan Kettering Westchester (Limited protocol activities) Recruiting Harrison New York 10604 United States Details
Memorial Sloan-Kettering Cancer Center (All protocol activities) Recruiting New York New York 10065 United States Details
Memorial Sloan Kettering Nassau (Limited protocol activities) Recruiting Rockville Centre New York 11553 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field